ScinoPharm Completes China Plant - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ScinoPharm Completes China Plant

ScinoPharm has completed construction of  a R&D process-development center and a multipurpose API cGMP manufacturing plant in Changshu, China.
A total of $113 million was invested in this facility.  The new plant will work together with ScinoPharm Taiwan in the production of new and generic drugs for the international market as well as supply the local Chinese market.  The plant has already received drug production licenses from the Chinese FDA for four APIs products. The plant will also serve as the base for the company to develop its API business in China.  ScinoPharm has already developed nine of the top 20 oncological products used in China, according to the company.
The Changshu plant is equipped to manufacture high-potency, antitumor, hormonal-active pharmaceutical ingredients and intermediates in highly contained facilities. In addition, the plant is also able to manufacture new products in smaller quantities for sales evaluations and for GMP samples.
The company also has purchased an additional 108 acres of adjoining property to be used for the development of future API production lines and for the construction of future formulation production plants.

Source: ScinoPharm


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here